Edgewise Therapeutics Stock

edgewisetx.comHealthcare / BioTech & PharmaFounded: 2017Funding to Date: $65.5MM

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need.

Register for Details

For more details on financing and valuation for Edgewise Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Edgewise Therapeutics.

Register Today

Team

Management Team

Kevin Koch
Chief Executive Officer, President & Board Member
Alan Russell Ph.D
Co-Founder, Chief Scientific Officer & Board Member
Peter Thompson MD
Co-Founder & Chairman
Badreddin Edris Ph.D
Co-Founder & Board Observer

Board Members

Alan Russell Ph.D
Peter Thompson MD
Jonathan Root MD
US Venture Partners
Kenneth Harrison Ph.D
Novo Holdings
Badreddin Edris Ph.D
Robert Jackson MD
Deerfield Management

Other companies like Edgewise Therapeutics in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Edgewise Therapeutics : Closes $50 Million Series B Financing
Edgewise Therapeutics Raises $50M in Series B Financing | FinSMEs
Edgewise Therapeutics, a preclinical company developing small molecule therapies for musculoskeletal diseases, closed a $50m Series B financing
Updated on: Oct 2, 2023

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.